05 September 2022

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the PVRI Working Group on PH Group 3

By Sylvia M. NikkhoManuel J. RichterEric ShenSteven H. AbmanKaterina AntoniouJonathan ChungPeter FernandesPaul HassounHoward M. LazarusHorst OlschewskiLucilla PiccariMitchell PsotkaRajan SaggarOksana A. ShlobinNorman StockbridgePatrizio VituloCarmine Dario VizzaStephen J. Wort and Steven D. Nathan, on behalf of the Pulmonary Vascular Research Institute.

Abstract

Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly associated with decreased exercise and functional capacity, an increased risk of hospitalizations and death. Examining the scope of this issue and its impact on patients is the first step in trying to define a roadmap to facilitate and encourage future research in this area. The aim of our working group is to strengthen the communities understanding of PH due to lung diseases and to improve the care and quality of life of affected patients. This introductory statement provides a broad overview and lays the foundation for further in-depth papers on specific topics pertaining to PH-ILD.


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg